Refoxy Pharma
Key Facts
| Invested since | 2024 |
| Based in | North Rhine-Westphalia |
About the company
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and elicit unique therapeutic effects. The company is developing a pipeline of therapeutics, with an initial focus on fibrotic disorders, particularly IPF. Refoxy is based in Cologne, Germany.
Do you want to
know more about this company?
Zum Artikel
Dr. Christian Kannemeier Senior Investment Manager
Dr. Christian KannemeierSenior Investment Manager
Refoxy Pharma in the news
Zum Artikel
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis
More startups from Life Sciences
Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists …
To the complete profileof Smarterials Technology
Exit
cytena’s single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with …
To the complete profileof Cytena
VACIS is the leading tissue engineering company for body-own blood vessels. The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing …
To the complete profileof Vacis
Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible …
To the complete profileof cutanos
mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …
To the complete profileof mediaire
Exit
multiBIND develops innovative solutions for molecular biology, healthcare and agriculture. bioDECONT® and bioCLEAN represent biocompatible disinfection and decontamination in laboratories, hospitals and agriculture.
To the complete profileof multiBIND
Exit
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
To the complete profileof CARDIOR
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
Exit
Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.
To the complete profileof Sierra Sensors
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The …
To the complete profileof Dimericon
Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific director is Priv.-Doz. Dr. Julian Keil. The Nuuron team consists of experts in the fields of neuroscience, medicine, …
To the complete profileof Nuuron